ClinicalTrials.gg
RecruitingNCT06824688Updated Nov 19, 2026

Single-port Versus Multi-port Robotic Surgery for Rectal Cancer

An interventional study of Single-port robotic total mesorectal excision and Multi-port robotic total mesorectal excision in Rectal Cancer Patients and Robotic Surgical Procedures, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
293rd of 373
40 · median 100
Started
2025
with 68 others
No phase
133 of 463
58 open now
Primary completion
2027-12
later than 185 of 266 live
Registered
334th of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 293rd largest by planned enrollment of the 373 interventional ones that give a count, is one of 69 that started in 2025, is one of 133 with no phase, reaches primary completion later than 185 of the 266 other live ones, and was the 334th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Single-port versus multi-port robotic surgery for rectal cancer

Read the detailed description

This study is a stage 2 clinical trial based on the IDEAL framework, which aims to evaluate the safety and short-term clinical efficacy of single-port robotic total mesorectal excision by comparing it with multi-port robotic total mesorectal excision. The primary endpoint is short-term clinical efficacy, including intraoperative complications, blood loss, conversion rate, operation time, postoperative complications within 30 days, time to first flatus after surgery, and postoperative hospital stay. Secondary endpoints include incision length, visual analog scale (VAS) scores for postoperative pain on days 1-3, completeness of mesorectal excision grading, positive circumferential resection margin rate, positive distal resection margin rate, and the number of harvested lymph nodes.

This study was conducted in two phases:

Phase I (Stage 2a): A single-arm study of single-port robotic radical resection for rectal cancer (n=20) Phase II (Stage 2b): A prospective non-randomized controlled study comparing single-port (n=100) versus multi-port (n=100) robotic radical resection for rectal cancer

03

Conditions studied

  • Rectal Cancer Patients
  • Robotic Surgical Procedures

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria comprised: (1) MRI-confirmed distal tumor margin \<15 cm from the anal verge, (2) -proven adenocarcinoma, (3) clinical stage I-III (AJCC 8th edition) with potential downstaging post- therapy, (4) intent-to-treat with sphincter preservation and primary anastomosis, (5) documented , and (6) adult patients (≥18 years).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single-port robotic total mesorectal excision

    Single-port robotic total mesorectal excision

    Procedure: Single-port robotic total mesorectal excision

  • Active comparator
    Multi-port robotic total mesorectal excision

    Multi-port robotic total mesorectal excision

    Procedure: Multi-port robotic total mesorectal excision

Interventions

  • ProcedureSingle-port robotic total mesorectal excision

    Single-port robotic total mesorectal excision

  • ProcedureMulti-port robotic total mesorectal excision

    Multi-port robotic total mesorectal excision

06

What researchers measure

Primary outcomes

  1. Incidence of perioperative complications

    Perioperative complications will be described using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v. 4.03 criteria. Complications will refer to any medical occurrence directly attributed to the surgical procedure during and within the first 30 days.

    Time frame: Intraoperative and postoperative 30 days

  2. Number of participants with conversion procedures

    The number of patients converted from robotic to open or laparoscopic surgery

    Time frame: Date of surgery (Day 1)

Secondary outcomes

  1. Pain scores

    Visual Analog Scale (VAS) pain scores for patients on postoperative days 1-3

    Time frame: Postoperative days 1-3

  2. Quality of specimen

    As proposed and published by Quirke et al(Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002 Apr 1;20(7):1729-34.)

    Time frame: Date of surgery (Day 1)

  3. Total length of incisions

    Total length of all abdominal incisions (measured in millimeters).

    Time frame: Date of surgery (Day 1)

07

Study locations

1 of 1 sites recruiting
  • Huichao Zheng
    Chongqing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results, with data dictionary and statistical analysis plan, available 9-36months after publication to researchers with a methodologically sound proposal approved by the institutional data accesscommittee and a signed data access agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning 9 months and ending 36 months after publication of the primary results Article.

Access criteria: Methodologically sound proposal; approval by Daping Hospital institutional data access committee; signed data access agreement; no re-identification; no third-party transfer; no commercial use.

Data sharing details ↗ · www.dph-fsi.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 32 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Feb 13, 2025
StartActual
Apr 26, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: data sharing statement
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06824688
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Apr 26, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Huichao Zheng, MD
Contact
625730455@qq.com
68757350
Fan Li
study director · Army Medical Center (Daping Hospital), Army Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion